Search Results - "Mager, D E"

Network-Based Approaches in Drug Discovery and Early Development by Harrold, J M, Ramanathan, M, Mager, D E

“…Identification of novel targets is a critical first step in the drug discovery and development process. Most diseases such as cancer, metabolic disorders, and…”
Get full text

Development of Translational Pharmacokinetic-Pharmacodynamic Models by Mager, DE, Jusko, WJ

“…Contemporary models in the field of pharmacokinetic–pharmacodynamic (PK–PD) modeling often incorporate the fundamental principles of capacity limitation and…”
Get full text

Physical and Cognitive Performance and Burden of Anticholinergics, Sedatives, and ACE Inhibitors in Older Women by Cao, Y‐J, Mager, DE, Simonsick, EM, Hilmer, SN, Ling, SM, Windham, BG, Crentsil, V, Yasar, S, Fried, LP, Abernethy, DR

“…Polypharmacy, common in older people, confers both risk of adverse outcomes and benefits. We assessed the relationship of commonly prescribed medications with…”
Get full text

Semi-mechanistic Population Pharmacokinetic Model of Multivalent Trastuzumab Emtansine in Patients with Metastatic Breast Cancer by Chudasama, V L, Schaedeli Stark, F, Harrold, J M, Tibbitts, J, Girish, S R, Gupta, M, Frey, N, Mager, D E

“…Trastuzumab emtansine (T‐DM1) is an antibody–drug conjugate (ADC) composed of multiple molecules of the antimicrotubule agent DM1 linked to trastuzumab, a…”
Get full text

A Six‐Stage Workflow for Robust Application of Systems Pharmacology by Gadkar, K, Kirouac, DC, Mager, DE, van der Graaf, PH, Ramanujan, S

“…Quantitative and systems pharmacology (QSP) is increasingly being applied in pharmaceutical research and development. One factor critical to the ultimate…”
Get full text

The ISoP Standards and Best Practices Committee by Bruno, R, Mentré, F, Tannenbaum, S, Wang, Y, Corrigan, B, Mager, D E

“…The mission of the International Society of Pharmacometrics (ISoP) Standards and Best Practices Committee is to provide best practices and recommendations for…”
Get full text

Potency, continence and complication rates in 1,870 consecutive radical retropubic prostatectomies by Catalona, W J, Carvalhal, G F, Mager, D E, Smith, D S

“…We update results in a series of consecutive patients treated with anatomic radical retropubic prostatectomy regarding recovery of erections, urinary…”
Get more information

Pharmacokinetic/Pharmacodynamic Modeling of Renin Biomarkers in Subjects Treated With the Renin Inhibitor Aliskiren by Hong, Y, Dingemanse, J, Mager, DE

“…A semimechanistic pharmacokinetic/pharmacodynamic (PK/PD) model was developed to evaluate the effects of aliskiren on the renin–angiotensin system (RAS) in…”
Get full text

Population Pharmacokinetics and Dose Optimization of Mycophenolic Acid in HCT Recipients Receiving Oral Mycophenolate Mofetil by Li, H., Mager, D.E., Sandmaier, B.M., Maloney, D.G., Bemer, M.J., McCune, J.S.

“…We sought to create a population pharmacokinetic model for total mycophenolic acid (MPA), to study the effects of different covariates on MPA pharmacokinetics,…”
Get full text

A phase I clinical and pharmacokinetic study of the multi-drug resistance protein-1 (MRP-1) inhibitor sulindac, in combination with epirubicin in patients with advanced cancer by O'CONNOR, R, O'LEARY, M, FENNELLY, D, CLYNES, M, CROWN, J, BALLOT, J, COLLINS, C. D, KINSELLA, P, MAGER, D. E, ARNOLD, R. D, O'DRISCOLL, L, LARKIN, A, KENNEDY, S

“…Multi-drug resistance mediated by ATP-binding cassette trans-membrane protein pumps is an important cause of cancer treatment failure. Sulindac has been shown…”
Get full text

Mechanistic Vs. Empirical Network Models of Drug Action by Birtwistle, MR, Mager, DE, Gallo, JM

“…Declining success rates coupled with increased costs is leading to an inevitable breaking point in the drug development pipeline. Can we avoid it by…”
Get full text

From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building by Putnins, M., Campagne, O., Mager, D. E., Androulakis, I. P.

“…Quantitative Systems Pharmacology (QSP) models capture the physiological underpinnings driving the response to a drug and express those in a semi-mechanistic…”
Get full text

Bridging Sunitinib Exposure to Time‐to‐Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker by Ait‐Oudhia, S, Mager, DE, Pokuri, V, Tomaszewski, G, Groman, A, Zagst, P, Fetterly, G, Iyer, R

“…Hepatocellular carcinoma (HCC) is third in cancer‐related causes of death worldwide and its treatment is a significant unmet medical need. Sunitinib is a…”
Get full text

Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL‐1β Kinetics by Ait‐Oudhia, S, Lowe, PJ, Mager, DE

“…Canakinumab, an anti‐interleukin‐1β (IL‐1β) monoclonal antibody, is approved for cryopyrin‐associated periodic syndromes and is under investigation for the…”
Get full text

Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men by Smith, D S, Carvalhal, G F, Mager, D E, Bullock, A D, Catalona, W J

“…We evaluated differences in the prostate cancer detection rate among black and white men with serum prostate specific antigen (PSA) levels between 2.6 and 4.0…”
Get more information

Physiologically-Based Pharmacokinetic-Pharmacodynamic Modeling of 1 ,25-Dihydroxyvitamin D3 in Mice by Ramakrishnan, V., Yang, Q. J., Quach, H. P., Cao, Y., Chow, E. C. Y., Mager, D. E., Pang, K. S.

Get full text

Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer by Ramos, C G, Carvalhal, G F, Smith, D S, Mager, D E, Catalona, W J

“…We compare clinicopathological features, and cancer recurrence and survival rates in men with stage T1c versus T2a or T2b prostate cancer. From 1988 through…”
Get more information

Digital rectal examination for detecting prostate cancer at prostate specific antigen levels of 4 ng./ml. or less by Carvalhal, G F, Smith, D S, Mager, D E, Ramos, C, Catalona, W J

“…We evaluated the detection rate of prostate cancer in men with suspicious digital rectal examination findings and serum prostate specific antigen (PSA) 4…”
Get more information

Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition by Mager, Donald E, Krzyzanski, Wojciech

“…The aim of this study is to derive and evaluate an equilibrium model of a previously developed general pharmacokinetic model for drugs exhibiting…”
Get full text

Comparing assessments of DSM-IV substance dependence disorders using CIDI-SAM and SCAN by Compton, Wilson M., Cottler, Linda B., Dorsey, Karen B., Spitznagel, Edward L., Magera, Douglas E.

“…The main question addressed by this paper is whether DSM-IV substance dependence diagnoses obtained from two different instruments (the semi-structured WHO…”
Get full text